A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05735483 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

310

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis
Eczema

Interventions

DRUG: Lebrikizumab
DRUG: Placebo

Sponsor

Eli Lilly and Company